EXACT Therapeutics AS (OSL: EXTX)
Norway
· Delayed Price · Currency is NOK 3.400
-0.060 (-1.73%)
At close: Jan 17, 2025
EXACT Therapeutics AS Income Statement
Financials in millions NOK. Fiscal year is January - December.
Millions NOK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2017 |
| Other Revenue | - | 0 | 0.45 | 0.05 | - | 0.09 | Upgrade
|
| Revenue | - | 0 | 0.45 | 0.05 | - | 0.09 | Upgrade
|
| Revenue Growth (YoY) | - | -99.02% | 774.07% | - | - | -98.42% | Upgrade
|
| Gross Profit | - | 0 | 0.45 | 0.05 | - | 0.09 | Upgrade
|
| Selling, General & Admin | 22.25 | 22.55 | 14.58 | 18.52 | 14.56 | 5.62 | Upgrade
|
| Other Operating Expenses | 31.36 | 23.74 | 24.64 | 38.83 | 19.06 | 10.05 | Upgrade
|
| Operating Expenses | 55.83 | 48.38 | 41.23 | 59.16 | 34.7 | 16.07 | Upgrade
|
| Operating Income | -55.83 | -48.38 | -40.77 | -59.11 | -34.7 | -15.98 | Upgrade
|
| Interest Expense | - | -0.09 | -0.1 | -0.1 | -0.02 | -0.01 | Upgrade
|
| Interest & Investment Income | 1.81 | 0.95 | 0.48 | 0.34 | 0.07 | 0.06 | Upgrade
|
| Currency Exchange Gain (Loss) | -1.12 | -1.12 | 0.22 | 0.01 | 0.7 | 0.34 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.25 | 0.25 | -0.4 | 0.27 | 0.92 | 0.61 | Upgrade
|
| EBT Excluding Unusual Items | -54.89 | -48.38 | -40.57 | -58.59 | -33.04 | -15 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | -0.05 | 0.17 | Upgrade
|
| Pretax Income | -54.89 | -48.38 | -40.57 | -58.59 | -33.09 | -14.82 | Upgrade
|
| Income Tax Expense | -0.05 | -0.05 | -0.46 | - | - | - | Upgrade
|
| Net Income | -54.84 | -48.33 | -40.1 | -58.59 | -33.09 | -14.82 | Upgrade
|
| Net Income to Common | -54.84 | -48.33 | -40.1 | -58.59 | -33.09 | -14.82 | Upgrade
|
| Shares Outstanding (Basic) | 33 | 32 | 30 | 30 | 30 | 19 | Upgrade
|
| Shares Outstanding (Diluted) | 33 | 32 | 30 | 30 | 30 | 19 | Upgrade
|
| Shares Change (YoY) | 10.41% | 6.95% | 0.06% | 0.04% | 59.72% | 24.69% | Upgrade
|
| EPS (Basic) | -1.66 | -1.51 | -1.34 | -1.95 | -1.10 | -0.79 | Upgrade
|
| EPS (Diluted) | -1.66 | -1.51 | -1.34 | -1.95 | -1.10 | -0.79 | Upgrade
|
| Free Cash Flow | -48.17 | -47.39 | -34.1 | -56.74 | -29.95 | -13.86 | Upgrade
|
| Free Cash Flow Per Share | -1.45 | -1.48 | -1.14 | -1.89 | -1.00 | -0.74 | Upgrade
|
| Gross Margin | - | 100.00% | 100.00% | 100.00% | - | 100.00% | Upgrade
|
| Operating Margin | - | -1085224.09% | -8971.05% | -113674.66% | - | -18112.42% | Upgrade
|
| Profit Margin | - | -1084201.23% | -8823.56% | -112673.43% | - | -16799.67% | Upgrade
|
| Free Cash Flow Margin | - | -1062987.39% | -7503.15% | -109106.39% | - | -15710.68% | Upgrade
|
| EBITDA | -54.07 | -46.75 | -39.3 | -57.66 | -33.95 | -15.7 | Upgrade
|
| D&A For EBITDA | 1.76 | 1.63 | 1.48 | 1.45 | 0.75 | 0.28 | Upgrade
|
| EBIT | -55.83 | -48.38 | -40.77 | -59.11 | -34.7 | -15.98 | Upgrade
|
| Revenue as Reported | - | 0 | 0.45 | 0.05 | - | 0.09 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.